Implementation of Out-of-HOspital Administration of the Long-Acting Combination Cabotegravir+Rilpivirine as an Optional Therapy in HIV-Infected Patients From Spain: Acceptability, Appropriateness, Feasibility and Satisfaction: The HOLA Study
Latest Information Update: 16 May 2025
At a glance
- Drugs Cabotegravir (Primary) ; Rilpivirine (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms HOLA; The HOLA Study
Most Recent Events
- 09 May 2025 Planned End Date changed from 1 Mar 2025 to 1 Jun 2025.
- 09 May 2025 Planned primary completion date changed from 1 Mar 2025 to 1 Jun 2025.
- 11 Jun 2024 Status changed from recruiting to active, no longer recruiting.